Loading...
Stem cell transplantation is often considered for symptomatic sickle cell disease (SCD) patients with human leukocyte antigen (HLA)-identical sibling donors. However, outcomes of such transplants have previously been described only from single centers or research trials.
To report outcomes after HLA-identical sibling transplantation for SCD more broadly, investigators have conducted a retrospective, registry-based survey of 1000 patients (median age, 9.4 years; 86% were children) at 106 centers in 23 countries. Bone-marrow stem cells were used in 83.9% of transplantations, and most patients had myeloablative conditioning.
Results at a median follow-up of 54.5 months were as follows:
68% were full-donor chimera, 29% were mixed chimera, and only…